Summary: Curcumin, a substance found in turmeric, improves both mood and memory in people with mild, age related memory loss, researchers report.
Source: UCLA.
Lovers of Indian food, give yourselves a second helping: Daily consumption of a certain form of curcumin — the substance that gives Indian curry its bright color — improved memory and mood in people with mild, age-related memory loss, according to the results of a study conducted by UCLA researchers.
The research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin’s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer’s disease.
Found in turmeric, curcumin has previously been shown to have anti-inflammatory and antioxidant properties in lab studies. It also has been suggested as a possible reason that senior citizens in India, where curcumin is a dietary staple, have a lower prevalence of Alzheimer’s disease and better cognitive performance.
“Exactly how curcumin exerts its effects is not certain, but it may be due to its ability to reduce brain inflammation, which has been linked to both Alzheimer’s disease and major depression,” said Dr. Gary Small, director of geriatric psychiatry at UCLA’s Longevity Center and of the geriatric psychiatry division at the Semel Institute for Neuroscience and Human Behavior at UCLA, and the study’s first author.
The double-blind, placebo-controlled study involved 40 adults between the ages of 50 and 90 years who had mild memory complaints. Participants were randomly assigned to receive either a placebo or 90 milligrams of curcumin twice daily for 18 months.
All 40 subjects received standardized cognitive assessments at the start of the study and at six-month intervals, and monitoring of curcumin levels in their blood at the start of the study and after 18 months. Thirty of the volunteers underwent positron emission tomography, or PET scans, to determine the levels of amyloid and tau in their brains at the start of the study and after 18 months.
The people who took curcumin experienced significant improvements in their memory and attention abilities, while the subjects who received placebo did not, Small said. In memory tests, the people taking curcumin improved by 28 percent over the 18 months. Those taking curcumin also had mild improvements in mood, and their brain PET scans showed significantly less amyloid and tau signals in the amygdala and hypothalamus than those who took placebos.
The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.
Four people taking curcumin, and two taking placebos, experienced mild side effects such as abdominal pain and nausea.
The researchers plan to conduct a follow-up study with a larger number of people. That study will include some people with mild depression so the scientists can explore whether curcumin also has antidepressant effects. The larger sample also would allow them to analyze whether curcumin’s memory-enhancing effects vary according to people’s genetic risk for Alzheimer’s, their age or the extent of their cognitive problems.
“These results suggest that taking this relatively safe form of curcumin could provide meaningful cognitive benefits over the years,” said Small, UCLA’s Parlow–Solomon Professor on Aging.
The paper’s authors, in addition to Small, are Prabha Siddarth, Dr. Zhaoping Li, Karen Miller, Linda Ercoli, Natacha Emerson, Jacqueline Martinez, Koon-Pong Wong, Jie Liu, Dr. David Merrill, Dr. Stephen Chen, Susanne Henning, Nagichettiar Satyamurthy, Sung-Cheng Huang, Dr. David Heber and Jorge Barrio, all of UCLA.
Theravalues Corp. provided the curcumin and placebos for the trial, as well as funds for laboratory testing and for Small’s travel to present preliminary findings at the 2017 Alzheimer’s Association International Conference.
Funding: The study was supported by the Ahmanson Foundation, the Marshall and Margherite McComb Foundation, the McMahan Foundation, Bob and Marion Wilson, the Fran and Ray Stark Foundation Fund for Alzheimer’s Disease Research, the U.S. Department of Energy and the National Institutes of Health.
Source: Leigh Hopper – UCLA
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is credited to UCLA.
Original Research: Open access research in The American Journal of Geriatric Psychiatry.
doi:10.1016/j.jagp.2017.10.010
[cbtabs][cbtab title=”MLA”]UCLA “Curcumin Improves Memory and Mood.” NeuroscienceNews. NeuroscienceNews, 23 January 2018.
<https://neurosciencenews.com/curcumin-mood-memory-8346/>.[/cbtab][cbtab title=”APA”]UCLA (2018, January 23). Curcumin Improves Memory and Mood. NeuroscienceNews. Retrieved January 23, 2018 from https://neurosciencenews.com/curcumin-mood-memory-8346/[/cbtab][cbtab title=”Chicago”]UCLA “Curcumin Improves Memory and Mood.” https://neurosciencenews.com/curcumin-mood-memory-8346/ (accessed January 23, 2018).[/cbtab][/cbtabs]
Abstract
Preterm birth leads to hyper-reactive cognitive control processing and poor white matter organization in adulthood
Objective
Because curcumin’s anti-inflammatory properties may protect the brain from neurodegeneration, we studied its effect on memory in non-demented adults and explored its impact on brain amyloid and tau accumulation using 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile positron emission tomography (FDDNP-PET).
Methods
Forty subjects (age 51–84 years) were randomized to a bioavailable form of curcumin (Theracurmin® containing 90 mg of curcumin twice daily [N = 21]) or placebo (N = 19) for 18 months. Primary outcomes were verbal (Buschke Selective Reminding Test [SRT]) and visual (Brief Visual Memory Test-Revised [BVMT-R]) memory, and attention (Trail Making A) was a secondary outcome. FDDNP-PET signals (15 curcumin, 15 placebo) were determined in amygdala, hypothalamus, medial and lateral temporal, posterior cingulate, parietal, frontal, and motor (reference) regions. Mixed effects general linear models controlling for age and education, and effect sizes (ES; Cohen’s d) were estimated.
Results
SRT Consistent Long-Term Retrieval improved with curcumin (ES = 0.63, p = 0.002) but not with placebo (ES = 0.06, p = 0.8; between-group: ES = 0.68, p = 0.05). Curcumin also improved SRT Total (ES = 0.53, p = 0.002), visual memory (BVMT-R Recall: ES = 0.50, p = 0.01; BVMT-R Delay: ES = 0.51, p = 0.006), and attention (ES = 0.96, p < 0.0001) compared with placebo (ES = 0.28, p = 0.1; between-group: ES = 0.67, p = 0.04). FDDNP binding decreased significantly in the amygdala with curcumin (ES = −0.41, p = 0.04) compared with placebo (ES = 0.08, p = 0.6; between-group: ES = 0.48, p = 0.07). In the hypothalamus, FDDNP binding did not change with curcumin (ES = −0.30, p = 0.2), but increased with placebo (ES = 0.26, p = 0.05; between-group: ES = 0.55, p = 0.02).
Conclusions
Daily oral Theracurmin may lead to improved memory and attention in non-demented adults. The FDDNP-PET findings suggest that symptom benefits are associated with decreases in amyloid and tau accumulation in brain regions modulating mood and memory.
